Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Abingdon Health PLC ( (GB:ABDX) ) has issued an announcement.
Abingdon Health plc, a specialist in rapid diagnostic test development, manufacturing and regulatory services, has an international footprint with headquarters in York, UK, laboratories in Doncaster, and laboratories and commercial offices in Madison, Wisconsin. The Group supports med-tech and in vitro diagnostic customers with lateral flow assay development, regulatory consulting and analytical testing across multiple healthcare and environmental segments.
The company announced that its ordinary shares have commenced trading on the OTCQB Venture Market in the United States under the ticker ABDXF, while remaining listed on London’s AIM under ABDX. By utilising the OTCQB framework, Abingdon can broaden its access to U.S. investors without incurring additional SEC reporting obligations, potentially improving liquidity and visibility in North America while keeping ongoing compliance costs low.
This dual-trading arrangement positions Abingdon to reach a wider international shareholder base at a relatively modest cost, aligning with its global customer focus in diagnostics and med-tech services. The move may enhance the company’s capital markets profile and support future strategic initiatives by making its equity more accessible to U.S. institutional and retail investors.
Spark’s Take on ABDX Stock
According to Spark, TipRanks’ AI Analyst, ABDX is a Neutral.
The score is primarily held back by weak profitability and negative operating cash flow despite strong revenue growth. Technicals are supportive due to price strength and positive MACD, but overbought momentum signals add risk. Valuation is constrained by negative earnings (negative P/E) and no dividend yield data.
To see Spark’s full report on ABDX stock, click here.
More about Abingdon Health PLC
Abingdon Health plc is a UK-headquartered med-tech contract service provider specialising in rapid diagnostic tests and regulatory services for the in vitro diagnostic and wider medical device industry. The Group offers contract development and manufacturing of lateral flow assays, regulatory consulting, and analytical testing to support customers from concept through to commercial-scale production across markets including infectious disease, clinical testing, animal health and environmental applications.
Through its CDMO operations, Abingdon Health provides lateral flow product development, technology transfer and manufacturing for clients seeking to develop new assays or convert laboratory-based tests to rapid formats. Its regulatory units, Compliance Solutions (Life Sciences) and IVDeology, assist with quality systems, technical documentation and approvals across the USA, EU and UK, while subsidiary Abingdon Analytical delivers performance evaluation and data generation from its Doncaster laboratories, complementing facilities in York and Madison, Wisconsin.
Average Trading Volume: 199,667
Technical Sentiment Signal: Buy
Current Market Cap: £21.97M
For detailed information about ABDX stock, go to TipRanks’ Stock Analysis page.